Alfonso Quintas-Cardama - JoVE Visualize

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Clinical Lymphoma, Myeloma & Leukemia|December 17, 2013

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phaseMaro Ohanian, Hagop M Kantarjian, Alfonso Quintas-Cardama, et al.

American Journal of Hematology|July 31, 2016

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.

Blood|August 9, 2013

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.

Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Clinical Lymphoma, Myeloma & Leukemia|December 17, 2013

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phaseMaro Ohanian, Hagop M Kantarjian, Alfonso Quintas-Cardama, et al.

American Journal of Hematology|July 31, 2016

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.

Blood|August 9, 2013

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.

Pageof 4